Bergen, Norway 9 June 2022
Lifecare has recently concluded successful in-vitro test results of theminiaturized Sencell sensor. This represents a milestone achievement of theSencell development, and the impact of the in-vitro tests reaches even further.Learn more about the importance of these test results, as well as furtherincrease of staff in the Lifecare Group, a nationwide press coverage in severalNorwegian regional papers, a continued positive revenue at Lifecare Laboratory,and download Lifecares updated investor presentation.
Read more in the Lifecare June newsletter:https://lifecare.attme.dev/news/information-from-lifecare-june/
Lifecare's updated investor presentation is attached, it can also be downloadedat the company's webpage.
This is Lifecare Lifecare is a Bergen-based technology company developing a miniaturizedimplantable long-term sensor for correct and continuous monitoring of bloodsugar in people with diabetes. The Company's patented technology also has thepotential for use in various biomarkers. Lifecare AS is listed on EuronextGrowth (LIFE).
Further information Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.attme.dev,+47 40 05 90 40
This stock exchange announcement was published by Kine Hereid, InvestorRelations at Lifecare AS, on 09.06.22 at 08:30 CET.